LLY Stock Summary and Trading Ideas (Eli Lilly And Company | NYSE:LLY)

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly And Company trades on the NYSE stock market under the symbol LLY.

As of February 21, 2025, LLY stock price climbed to $873.68 with 3,426,839 million shares trading.

LLY has a market cap of $784.71 billion. This is considered a Mega Cap stock.

Last quarter Eli Lilly And Company reported $14 billion in Revenue and $5.32 earnings per share. This beat revenue expectation by $103 million and exceeded earnings estimates by $.24.

In the last 3 years, LLY traded as high as $972.53 and as low as $234.00.

The top ETF exchange traded funds that LLY belongs to (by Net Assets): VTI, VOO, SPY, IVV, VUG.

LLY has underperformed the market in the last year with a price return of +17.9% while the SPY ETF gained +22.1%. However, in the short term, LLY had mixed performance relative to the market. It has outperformed in the last 3 months, returning +16.7% vs +1.4% return in SPY. But in the last 2 weeks, LLY shares have been beat by the market, returning -0.4% compared to an SPY return of -0.1%.

LLY support price is $856.12 and resistance is $890.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LLY shares will trade within this expected range on the day.